Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Current use of beta-blockers in patients with coronary artery disease

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Editorial Commentary: When should the patient with an inherited cardiac disease have an ICD?

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  2. Editorial commentary: Subclinical thyroid dysfunction and cardiovascular risk: Nothing to lose, everything to gain?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Change in body mass index from childhood onwards and risk of adult cardiovascular disease

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. An overview of current and emerging devices for percutaneous left atrial appendage closure

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Time trends in incidence, comorbidity, and mortality of ischemic stroke in Denmark, 1996-2016

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prevalence and incidence of various Cancer subtypes in patients with heart failure vs matched controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Beta-blockers have long comprised a cornerstone in the symptomatic treatment of ischemic heart disease and in the secondary prevention of myocardial infarction and heart failure. The majority of studies underlying the evidence of a beneficial effect of beta-blockers on outcomes were conducted more than 25 years ago. In a contemporary era where treatment strategies and secondary prophylactic therapy have undergone several changes, the continued role of beta-blockers in ischemic heart disease has been questioned, especially in the absence of heart failure or a recent myocardial infarction. In summary, few randomized clinical trials are available on the effect of beta-blockers in the reperfusion era, especially on hard endpoints. Likewise, the results of numerous observational studies and meta-analysis are conflicting, emphasizing the need for additional large-scale randomized clinical trials to evaluate the role of beta-blocker therapy in current clinical practice.

OriginalsprogEngelsk
TidsskriftTrends in Cardiovascular Medicine
Vol/bind28
Udgave nummer6
Sider (fra-til)382-389
Antal sider8
ISSN1050-1738
DOI
StatusUdgivet - aug. 2018

ID: 56360359